Agenus Inc. (NASDAQ: AGEN) is a Healthcare company (Biotechnology) with a market capitalization of $281M. The Maz Rating grades it against the other companies in its sector.
Agenus Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.21, Agenus Inc. trades at 8.3x trailing earnings and 2.1x sales, with an EV/EBITDA of 2.8. Over the last twelve months it generated about $137M of revenue and $34M of net income. It runs an operating margin of 38.9% and a net margin of 23.0%. It shows return on equity of -15.5%, return on invested capital of 108.3% and a free cash flow yield of -36.9%. On the balance sheet: a debt-to-equity ratio of -0.37 and a current ratio of 0.73. Over the past 52 weeks the share price ranged from $2.71 to $10.31, with a beta of 1.52.
Agenus Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 10 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Agenus Inc. (AGEN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones and FTSE, and fails AAOIFI and MSCI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.92% / 30% · (Cash+Inv) / Mkt Cap (36m) 34.2% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 8.92% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 20.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 8.92% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 20.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 81.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 14.9% / 33.33% · Receivables / Avg Assets (4Q) 8.49% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 12.1% / 33.33% · (Cash+ST Inv) / Total Assets 27.3% / 33.33% · (Cash+Recv) / Total Assets 27.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Agenus Inc. (AGEN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones and FTSE, and fails AAOIFI and MSCI.
No. Agenus Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Agenus Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.